NTEC Intec Pharma Ltd.

0.52
-0.04  -6%
Previous Close 0.55
Open 0.57
Price To Book 1.05
Market Cap 18,355,629
Shares 35,641,999
Volume 250,012
Short Ratio
Av. Daily Volume 511,578
Stock charts supplied by TradingView

NewsSee all news

  1. Intec Pharma Issues Letter to Shareholders

    JERUSALEM, Jan. 9, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec" or "the Company") today provides a business and clinical update on its development programs with the Company's

  2. Intec Pharma Provides Update on Novartis Feasibility and Option Agreement

    JERUSALEM, Dec. 11, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec" or "the Company") today announces the termination of the Feasibility and Option agreement with Novartis for the

  3. Intec Pharma to Present at LD Micro's 12th Annual Main Event

    JERUSALEM, Dec. 6, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec" or "the Company") today announces that the Company management will be participating in the 12th Annual LD Micro Main Event

  4. Intec Pharma Announces $10 Million Ordinary Shares Purchase Agreement With Aspire Capital

    JERUSALEM, Dec. 3, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec" or "the Company") today announces that the Company has entered into an Ordinary Shares Purchase Agreement for $10.0

  5. Intec Pharma to Participate in Jefferies London Healthcare Conference

    JERUSALEM, Nov. 13, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec" or "the Company") today announces that Company management will participate in the Jefferies London Healthcare Conference. 

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released July 22, 2019 did not meet primary endpoint.
AP-CDLD
Advanced Parkinson's Disease
Phase 1 PK trial planned for 2020.
AP-THC
Various pain indications

Latest News

  1. Intec Pharma Issues Letter to Shareholders

    JERUSALEM, Jan. 9, 2020 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec" or "the Company") today provides a business and clinical update on its development programs with the Company's

  2. Intec Pharma Provides Update on Novartis Feasibility and Option Agreement

    JERUSALEM, Dec. 11, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec" or "the Company") today announces the termination of the Feasibility and Option agreement with Novartis for the

  3. Intec Pharma to Present at LD Micro's 12th Annual Main Event

    JERUSALEM, Dec. 6, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec" or "the Company") today announces that the Company management will be participating in the 12th Annual LD Micro Main Event

  4. Intec Pharma Announces $10 Million Ordinary Shares Purchase Agreement With Aspire Capital

    JERUSALEM, Dec. 3, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec" or "the Company") today announces that the Company has entered into an Ordinary Shares Purchase Agreement for $10.0

  5. Intec Pharma to Participate in Jefferies London Healthcare Conference

    JERUSALEM, Nov. 13, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec" or "the Company") today announces that Company management will participate in the Jefferies London Healthcare Conference. 

  6. Intec Pharma Reports Third Quarter 2019 Financial Results and Provides Business Update

    JERUSALEM, Nov. 12, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec" or "the Company") today announces financial results for the three and nine months ended September 30, 2019. Highlights of

  7. Intec Pharma Highlights Potential of Accordion Pill® Oral Drug Delivery Platform in Two Posters at International Congress of Parkinson's and Movement Disorder Society

    JERUSALEM, Sept. 25, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec" or "the Company") today announces that two posters highlighting data from the Company's Phase 3 clinical development

  8. Intec Pharma to Present Two Posters at International Congress of Parkinson's and Movement Disorder Society

    JERUSALEM, Sept. 16, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec" or "the Company") today announces that two posters in support of the Company's Phase 3 clinical development program

  9. Intec Pharma to Participate in September Investment Conferences

    JERUSALEM, Sept. 3, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming

  10. Thinking about buying stock in Aurora Cannabis, Lannett, Intec Pharma, Tilray, or Yelp?

    NEW YORK, Aug. 28, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, LCI, NTEC, TLRY, and YELP. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the